10th Circuit: EpiPen Competitor Lacks Evidence Mylan Harmed Consumers
Mealey's (August 2, 2022, 8:58 AM EDT) -- DENVER — The 10th Circuit U.S. Court of Appeals on July 29 affirmed a decision by the EpiPen multidistrict litigation court that Sanofi-Aventis U.S. LLC (Sanofi) could not show that Mylan...
To view the full article, register now.
Try for FREE for fourteen days
Already a subscriber? Click here to login